# 愛爾蘭 RNA 生技公司 Aerska 完成 3,900 萬美元 A 輪融資。

*biotech · news · 2026-02-10 · Siliconrepublic.com*

## Key points

- Aerska 完成 3,900 萬美元 A 輪融資，自創立以來總募資達 6,000 萬美元。
- Aerska 正在開發腦部穿梭技術，以將 RNAi 治療劑穿越血腦障壁。
- EQT Dementia Fund 與 Age1 領投本輪，並有新董事會成員來自這些投資者。
- 資金將推進針對遺傳性阿茲海默症及其他神經疾病的療法開發。

Having emerged from stealth in October 2025 with a seed round of $21m, Irish RNA biotech Aerska has now raised a $39m series A funding round. The latest raise brings total funds raised to $60m since launch. The young biotechnology company is using brain shuttle technology to develop RNA medicines for central nervous system diseases. The new round was led by EQT Dementia Fund and Age1, with participation from Iaso Ventures and existing investors. Aerska says the funding will be used to advance its brain shuttle technology “to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases”. “The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration,” said CEO Jack O’Meara, who co-founded Aerska alongside David Hardwicke and Stu Milstein. O’Meara had previously founded Ochre Bio in 2019, an RNA medicines company focused on liver disease. The company raised more than $100m in funding and secured a deal worth up to $1bn. He stepped away from the company in late 2024. “Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders,” O’Meara continued. As part of the financing, Arno de Wilde, managing director at EQT; Philip Scheltens, partner and head of the Dementia Fund at EQT; and Alex Colville, general partner at Age1, will join Aerska’s board of directors. “For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life,” said Scheltens. “The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches.” By “silencing the genes that cause harm”, Aerska aims to “preserve the minds, protect the memories, and enable our loved ones to live longer, healthier lives”. With its headquarters in Dublin, Aerska also has research operations in London in the UK.

**Companies:** Aerska
**Countries:** Ireland, United Kingdom

[Read the full story on Siliconrepublic.com](https://www.siliconrepublic.com/start-ups/irish-biotech-aerska-raises-39m-series-a-to-deliver-rna-meds-to-the-brain)

---

Canonical: https://newsio.io/zh-TW/n/c6593ce7-0296-4723-829d-4918fffb0ccf/rna-aerska-3900-a-6000-rna
Summarized by Newsio from Siliconrepublic.com. https://newsio.io/how-it-works